Mirae Asset ramps up investment in biotech sector Mirae Asset Capital investing in more than 10 foreign biotech and healthcare firms
Translated by Kim So-in 공개 2021-09-06 07:49:49
이 기사는 2021년 09월 06일 07:38 thebell 에 표출된 기사입니다.
Mirae Asset Group is ramping up its investments in the biotech sector, with Mirae Asset Capital increasing its investment in foreign biotech and healthcare startups.Mirae Asset Capital has invested in more than 10 foreign biotech and healthcare companies in recent years, according to data compiled by the bell. Investments have been mostly funded through Mirae Asset-Celltrion New Growth Fund I, which closed at 150 billion won ($130 million) in 2017.
The fund, which was created jointly by Mirae Asset Group and Celltrion, is managed by Mirae Asset Capital. The duration of the fund is seven years since the inception. It mainly invests in companies that engage in new growth engines like biotech and healthcare, such as biomaterials firms, new drug developers, and medical device companies. The fund mostly focuses on late-stage investments instead of early-stage investments.
The fund participated in U.S.-based Vividion Therapeutics’ Series B funding round in 2019. The investment is expected to generate a hefty profit as Bayer recently agreed to acquire the firm for $1.5 billion.
The fund invested in bispecific antibody startup EpimAb Biotherapeutics in the fourth quarter of 2020. It also participated in Senti Biosciences and Valo Health’s Series B funding rounds.
The fund is making more active investments this year, investing in Omega Therapeutics, Iksuda Therapeutics, and HiFiBiO Therapeutics.
Mirae Asset Venture Investment also invested in five foreign biotech firms during the first six months of this year, including Israel-based KAHR Medical and Singapore-based Hummingbird Bioscience.
The move is part of Mirae Asset Group Chairman Park Hyeon-joo’s plans to invest 10 trillion won over the next 10 years in startups engaged in new growth engines such as biopharmaceutical and healthcare sectors. (Reporting by In-hyo Kang)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [DL이앤씨 인사 격변]인적분할 4년차, '가이던스 달성 실패' 후폭풍 거셌다
- [DL이앤씨 인사 격변]CFO도 퇴출, 후임자 내외부 물색
- [DL이앤씨 인사 격변]감원 칼바람, 임원 10명 중 3명 짐 쌌다
- CJ올리브영, 글랜우드PE와 결별 '이사회 재정비'
- [코스닥 주총 돋보기]'상폐 위기' 엠벤처투자, 주주 해명 '안간힘'
- FI 지분 되사온 CJ올리브영, ‘승계 플랜’ 본격 가동하나
- 에스텍파마, 폴라리스AI파마로 '새 출발'
- 나무가, '공정 자동화 전문가' 이동호 대표이사 선임
- CJ그룹, 글랜우드PE에 판 CJ올리브영 지분 되사온다
- 고려아연, 강남 영풍빌딩 떠난다…행선지는 종로구